News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN), Bristol-Myers Squibb Company (BMY) Diabetes Pill Has Risks - FDA



7/15/2011 8:20:36 AM

U.S. drug reviewers said a new pill from Bristol-Myers Squibb Co (BMY.N) and AstraZeneca Plc (AZN.L) was effective in treating diabetes, but posed a number of safety risks. The pill, with the chemical name dapagliflozin, could also be less effective if patients had kidney problems, reviewers from the Food and Drug Administration said in documents released on Friday. In clinical trials, the drug has been linked to a higher number of bladder and breast cancer.

Read at Reuters
Read at Sacramento Bee
Read at Nasdaq


comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES